IGM Biosciences Files 8-K: Agreements, Officer Changes, and Disclosures
| Field | Detail |
|---|---|
| Company | Igm Biosciences, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, officer-changes, director-changes, disclosure
Related Tickers: IGMS
TL;DR
IGM Biosciences 8-K: New deals, exec shake-up, and financial updates filed July 1st.
AI Summary
On July 1, 2025, IGM Biosciences, Inc. filed an 8-K report detailing several key events. The company entered into a Material Definitive Agreement, announced the departure of directors or certain officers, elected new directors, appointed certain officers, and disclosed compensatory arrangements for these officers. The filing also included Regulation FD disclosures and financial statements with exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including new agreements and changes in leadership, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and changes in officers/directors, which can introduce uncertainty or signal strategic shifts.
Key Players & Entities
- IGM Biosciences, Inc. (company) — Registrant
- July 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39045 (legal_document_id) — SEC File Number
- 77-0349194 (tax_id) — IRS Employer Identification No.
FAQ
What is the nature of the Material Definitive Agreement entered into by IGM Biosciences?
The filing states that IGM Biosciences, Inc. entered into a Material Definitive Agreement, but the specific details of this agreement are not provided in the summary information of the 8-K filing.
Who are the directors or officers departing from IGM Biosciences?
The 8-K filing indicates the departure of directors or certain officers, but the names of these individuals are not specified in the provided summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on July 1, 2025.
What is the principal executive office address for IGM Biosciences?
The principal executive offices of IGM Biosciences are located at 325 E Middlefield Road, Mountain View, CA 94043.
What is the SIC code for IGM Biosciences?
The Standard Industrial Classification (SIC) code for IGM Biosciences is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 1, 2025 regarding IGM Biosciences, Inc..